{"filings":[{"id":721756,"accession_number":"0001628280-26-038793","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2026-05-28T20:04:39+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Corcept shareholders approve 8M-share increase to 2024 Incentive Award Plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to 2024 Incentive Award Plan, adding 8,000,000 authorized shares.","All eight director nominees elected; vote totals show majority support for each.","Ernst & Young ratified as independent auditor for fiscal 2026.","Advisory vote on named executive officer compensation passed with 72.5 million 'for' votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91203,"accession_number":"0001628280-26-028892","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Corcept Q1 revenue $164.9M (+5% YoY); raises 2026 guidance to $950-1050M; Lifyorli approved","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $164.9M, up 5% YoY from $157.2M. Net loss $31.8M vs net income $20.5M in Q1 2025 due to launch costs.","2026 revenue guidance raised to $950-$1,050M (from prior range).","FDA approved Lifyorli (relacorilant) for platinum-resistant ovarian cancer in March 2026; NCCN preferred regimen.","Cash and investments $515.4M at March 31, 2026. Expect return to profitability in Q2 2026.","ROSELLA trial results published in The Lancet; BELLA, SYNERGY, MONARCH, DAZALS trials ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":164903000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101169,"accession_number":"0001193125-26-123543","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA approves Corcept's Lifyorli (relacorilant) for platinum-resistant ovarian cancer","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Lifyorli (relacorilant) plus nab-paclitaxel approved for adults with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer.","Approval based on ROSELLA trial: 35% reduction in risk of death (HR 0.65, median OS 16.0 vs 11.9 months).","Lifyorli is the first FDA-approved selective glucocorticoid receptor antagonist (SGRA).","Most common adverse reactions: decreased hemoglobin, neutrophils, fatigue, nausea, diarrhea, rash, decreased appetite."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101168,"accession_number":"0001628280-26-011080","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Corcept Q4 revenue $202.1M, FY2025 $761.4M; guides FY2026 revenue $900M-$1B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $202.1M (vs $181.9M Q4 2024); full-year revenue $761.4M (vs $675.0M in 2024).","Diluted EPS: Q4 $0.20, FY2025 $0.82 (vs Q4 2024 $0.26, FY2024 $1.23). Net income declined due to stock repurchases and operational costs.","Cash and investments $532.4M at Dec 31, 2025; spent $245.9M on stock repurchases in 2025.","FY2026 revenue guidance $900M-$1B; expects continued Cushing's syndrome business growth.","PDUFA date July 11, 2026 for relacorilant NDA in platinum-resistant ovarian cancer; FDA engaged after CRL for Cushing's NDA."],"consensus_eps_estimate":null,"consensus_eps_actual":0.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":761407000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101167,"accession_number":"0001193125-26-059551","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Federal Circuit affirms Teva generic Korlym does not infringe two Corcept patents","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Court of Appeals for the Federal Circuit found Teva's generic Korlym does not infringe two Corcept patents on safe co-administration with CYP3A4 inhibitors.","Ruling affirms December 2023 District of New Jersey verdict; Corcept will consider further judicial review.","CEO Joseph Belanoff expressed disappointment and said company will vigorously defend its rights.","Patents cover methods used in treating Cushing's syndrome; generic entry would weaken Korlym's market exclusivity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101166,"accession_number":"0001193125-26-018704","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2026-01-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Corcept's ROSELLA Phase 3 trial meets overall survival endpoint; 35% risk reduction","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Relacorilant + nab-paclitaxel reduced risk of death by 35% vs. nab-paclitaxel alone (HR 0.65, p=0.0004).","Median OS 16.0 months vs. 11.9 months (4.1-month improvement); both dual primary endpoints met.","NDA under FDA review with PDUFA date of July 11, 2026; MAA under EMA review.","Relacorilant well-tolerated without increased safety burden; no biomarker selection required.","Trial enrolled 381 patients across US, Europe, South Korea, Brazil, Argentina, Canada, Australia."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117515,"accession_number":"0001193125-25-338184","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2025-12-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA issues Complete Response Letter for Corcept's relacorilant NDA in hypercortisolism","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA concluded benefit-risk assessment unfavorable without additional effectiveness evidence.","Pivotal GRACE trial met primary endpoint; GRADIENT trial provided confirmatory evidence.","CEO Joseph Belanoff expressed surprise and disappointment; plans to meet with FDA.","Relacorilant was under review for hypertension secondary to hypercortisolism."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117514,"accession_number":"0001628280-25-048814","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Corcept Q3 revenue rises to $207.6M but net income drops; 2025 guidance modified to $800-850M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $207.6M (+14% YoY); net income $19.7M ($0.16 diluted EPS) vs $47.2M ($0.41) in Q3 2024.","Modified 2025 revenue guidance to $800-850M, citing capacity constraints at prior specialty pharmacy.","Cash and investments $524.2M; repurchased $50.6M in stock during Q3.","NDA for relacorilant in hypercortisolism PDUFA Dec 30, 2025; NDA for ovarian cancer PDUFA July 11, 2026.","New oncology trials starting: Phase 2 in earlier-stage ovarian, endometrial, cervical, pancreatic cancers; Phase 1b for nenocorilant with immunotherapy."],"consensus_eps_estimate":null,"consensus_eps_actual":0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":559282000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117513,"accession_number":"0001193125-25-237834","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["1.02","9.01"],"status":"ready","headline":"Corcept terminates distribution agreement with Optime Care, effective Jan 8, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Notice of termination of Distribution Services Agreement with Optime Care given Oct 10, 2025; effective Jan 8, 2026.","Optime had been specialty pharmacy distributor for Korlym and authorized generic mifepristone.","Exclusive provider status ended Sept 15, 2025; termination is for convenience under 90-day notice provision.","Original agreement dated Aug 4, 2017, amended and restated Apr 1, 2024, with term through Mar 31, 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117512,"accession_number":"0001193125-25-231963","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2025-10-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director Gillian Cannon resigns from Corcept board; consulting agreement signed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Gillian Cannon resigned from the Board effective October 10, 2025, with no disagreement over operations or policies.","Company and Cannon entered consulting agreement from effective date until 2026 annual stockholder meeting.","Consulting fee: $5,708.33 per month; previously awarded stock options continue vesting per original schedule."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133931,"accession_number":"0001193125-25-199706","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2025-09-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA accepts Corcept's NDA for relacorilant in platinum-resistant ovarian cancer; PDUFA July 11, 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted Corcept's NDA for relacorilant in platinum-resistant ovarian cancer with a PDUFA date of July 11, 2026.","NDA based on positive Phase 3 ROSELLA and Phase 2 data showing improved PFS and OS without biomarker selection.","Relacorilant plus nab-paclitaxel was well-tolerated; adverse events similar to nab-paclitaxel monotherapy.","CEO Joseph Belanoff: 'FDA acceptance brings us closer to offering a much-needed treatment option for this dire disease.'","Relacorilant may redefine platinum-resistant ovarian cancer treatment, Corcept states."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133930,"accession_number":"0001628280-25-036999","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Corcept Q2 revenue rises 19% to $194.4M; 2025 guidance raised to $850-900M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $194.4M (+19% YoY); net income $35.1M vs $35.5M; diluted EPS $0.29 vs $0.32.","Modified 2025 revenue guidance to $850-900M; cash & investments $515M after $115.4M buyback.","NDA for relacorilant in hypercortisolism (PDUFA Dec 30, 2025); NDA submitted for ovarian cancer.","DAZALS: dazucorilant 300mg showed 84% reduced death risk (HR 0.16, p=0.0009); regulatory discussions.","Record new prescribers/patients; vendor capacity constraints offset demand; second pharmacy coming online."],"consensus_eps_estimate":null,"consensus_eps_actual":0.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":351644000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133929,"accession_number":"0001193125-25-158454","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2025-07-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Corcept submits NDA for relacorilant as treatment for platinum-resistant ovarian cancer","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NDA submitted to FDA for relacorilant plus nab-paclitaxel, based on Phase 3 ROSELLA and Phase 2 trials.","Improved progression-free and overall survival vs nab-paclitaxel monotherapy; no biomarker selection needed.","Relacorilant well-tolerated; adverse events similar to monotherapy, no increased safety burden.","CEO notes this is Corcept's second NDA before FDA; relacorilant also under review for hypercortisolism.","Company preparing launch once approved; oncology and endocrinology units in place."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150672,"accession_number":"0001628280-25-031624","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Corcept shareholders elect nine directors, ratify Ernst & Young, approve executive comp at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All nine director nominees elected with substantial support; David Mahoney received 62.7M for, 14.7M withheld.","Ernst & Young ratified as auditor for FY 2025 with 90.5M votes for, 1.5M against.","Advisory vote on executive compensation approved with 72.9M for, 4.2M against, 14.9M broker non-votes.","Total shares voted: 92.3M out of 106.0M eligible shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150671,"accession_number":"0001628280-25-022167","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Corcept Q1 revenue $157.2M (+7%); FY25 guide $900-950M reaffirmed; relacorilant & dazucorilant updates","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $157.2M, up 7% YoY; diluted EPS $0.17 vs $0.25; operating expenses rose to $153.8M from $117.3M.","Reiterated FY 2025 revenue guidance $900-950M; cash/investments $570.8M (down from $603.2M due to buybacks).","Relacorilant NDA for Cushing's under FDA review with PDUFA Dec 30, 2025; NDA for ovarian cancer expected Q3 2025.","Phase 3 ROSELLA trial met PFS and OS endpoints; results to be presented at ASCO June 2025.","Dazucorilant ALS trial missed primary endpoint; exploratory survival benefit at 1yr (HR 0.16, p=0.0009); seeking regulatory input."],"consensus_eps_estimate":null,"consensus_eps_actual":0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":157214000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169623,"accession_number":"0001193125-25-067871","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Corcept's Phase 3 ROSELLA trial of relacorilant meets primary endpoint; PFS and OS improved significantly","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["30% risk reduction in PFS (HR 0.70, p=0.008); median PFS 6.5 vs 5.5 months for nab-paclitaxel alone.","Interim OS also positive: median OS 16.0 vs 11.5 months (HR 0.69, p=0.012).","Relacorilant well-tolerated; no new safety signals; safety comparable between groups.","Company expects to submit NDA in Q3 2025 and MAA shortly thereafter.","Trial enrolled 381 patients globally; biomarker selection not required."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169622,"accession_number":"0001193125-25-044123","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA accepts Corcept's NDA for relacorilant in Cushing's syndrome; PDUFA Dec 30, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA filed relacorilant NDA for endogenous hypercortisolism (Cushing's syndrome).","PDUFA target action date set for December 30, 2025.","NDA supported by positive GRACE, GRADIENT, and Phase 2 trial results.","No drug-induced adrenal insufficiency, hypokalemia, or QT prolongation observed in trials.","CEO states relacorilant has potential to become new standard of care."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169621,"accession_number":"0001628280-25-008131","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Corcept Q4/FY2024: Revenue $675M (+40%), Net Income $141M; Guides 2025 $900-950M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $181.9M vs $135.4M YoY; FY revenue $675.0M (+40% YoY).","FY net income $141.2M ($1.23 diluted EPS) vs $106.1M ($0.94) in 2023.","2025 revenue guidance $900-$950M; cash and investments $603.2M at Dec 31, 2024.","NDA submitted for relacorilant for hypercortisolism; ROSELLA Phase 3 data expected this quarter.","DAZALS Phase 2 in ALS missed primary endpoint; showed survival benefit (0 vs 5 deaths at 24 weeks, p=0.02)."],"consensus_eps_estimate":null,"consensus_eps_actual":1.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":675040000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186683,"accession_number":"0001193125-24-286917","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2024-12-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Corcept submits NDA for relacorilant to treat Cushing's syndrome","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NDA based on positive pivotal GRACE trial, Phase 3 GRADIENT, long-term extension and Phase 2 studies.","No drug-induced adrenal insufficiency, hypokalemia, QT prolongation, or progesterone receptor effects seen.","CEO Joseph Belanoff states relacorilant has potential to become standard of care for hypercortisolism."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186682,"accession_number":"0001628280-24-044318","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Corcept Q3 revenue $182.5M (+48% YoY); guides FY2024 to $675-700M; positive GRADIENT results","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $182.5M (+48% YoY); diluted EPS $0.41 vs $0.28; net income $47.2M.","FY2024 revenue guidance raised to $675-700M from $640-670M; strong Korlym prescriber and patient growth.","Cash and investments $547.6M; repurchased 870K shares for $23.4M in Q3.","Phase 3 GRADIENT in Cushing's syndrome: significant improvements in BP, glucose, weight vs placebo; no hypokalemia or endometrial hypertrophy.","NDA for relacorilant in Cushing's to be submitted this quarter; ROSELLA (ovarian cancer) and DAZALS (ALS) data expected by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":0.98,"consensus_revenue_estimate":null,"consensus_revenue_actual":493150000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203240,"accession_number":"0001628280-24-033281","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2024-07-29T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Corcept Q2 revenue up 39% to $163.8M; raises 2024 guidance to $640-670M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $163.8M, up 39% YoY; diluted EPS $0.32 vs $0.25.","2024 revenue guidance raised to $640-670M from $620-650M.","Cash and investments $492.5M at June 30, up from $451M at March 31.","NDA submission for relacorilant in Cushing's syndrome expected Q4; late-stage trial results (ROSELLA, GRADIENT, DAZALS) due by year-end.","Record number of new Korlym prescribers and patients; hypercortisolism screening expanding."],"consensus_eps_estimate":null,"consensus_eps_actual":0.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":310604000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219578,"accession_number":"0001628280-24-024936","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Corcept Therapeutics shareholders approve 2024 Incentive Award Plan adding 8M new shares","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["2024 Plan replaces 2012 plan; total shares authorized = 8M new + 4,073,955 carryover + lapsed awards.","All 9 director nominees elected; vote range 56.9M to 65.6M for (excluding broker non-votes).","Ernst & Young ratified as auditor for FY2024: 86.6M for, 1.7M against.","Advisory say-on-pay approved: 64.5M for, 1.0M against; 22.5M broker non-votes.","2024 Plan passed with 47.0M for, 18.7M against; 22.5M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219577,"accession_number":"0001628280-24-019607","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Corcept Q1 revenue up 39% to $146.8M; raises FY2024 guidance to $620-650M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $146.8M (+39% YoY); diluted EPS $0.25 vs $0.14; net income $27.8M.","2024 revenue guidance raised to $620-650M from $600-630M.","Cash and investments $451.0M at March 31, 2024.","GRACE open-label phase showed significant improvements; NDA for relacorilant in Cushing's expected this quarter.","Enrollment completed in GRADIENT, CATALYST, ROSELLA, DAZALS; data expected by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":146808000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}